Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: European Surgery 6/2020

Open Access 08.10.2020 | original article

Fibroblast growth factor 8 overexpression is predictive of poor prognosis in pancreatic ductal adenocarcinoma

verfasst von: Gerd Jomrich, Lavinia Wilfing, Sanja Radosavljevic, Ario Parak, Daniel Winkler, Gerald Timelthaler, Martin Schindl, Sebastian F. Schoppmann, Bernhard Klösch

Erschienen in: European Surgery | Ausgabe 6/2020

download
DOWNLOAD
share
TEILEN
print
DRUCKEN
insite
SUCHEN

Summary

Background

Despite distinctive advances in the field of pancreatic cancer therapy over the past few years, patient survival remains poor. Fibroblast growth factors 8 (FGF8) and 18 (FGF18) both play a role in modulating the activity of malignant cells and have been identified as promising biomarkers in a number of cancers. However, no data exist on the expression of FGF8 and FGF18 in pancreatic ductal adenocarcinoma (PDAC).

Methods

Protein expression levels of FGF8 and FGF18 in postoperative specimens of neoadjuvantly treated and primarily resected patients were investigated using immunohistochemistry. Immunostaining scores were calculated as the products of the staining intensity and the staining rate. Scores exceeding the median score were considered as high expression.

Results

Specimens from 78 patients with PDAC were available and met the eligibility criteria for analysis of protein expression using immunohistochemistry. 15 (19.2%) patients had received neoadjuvant chemotherapy. High protein levels of FGF8 and FGF18 were detected in 40 (51.8%) and 33 (42.3%) patients, respectively. Kaplan–Meier analysis demonstrated significantly shorter overall survival in patients with high expression of FGF8 (p = 0.04). Multivariable Cox proportional hazard regression models revealed that high expression of FGF8 (Hazard ratio [HR] 0.53, 95% Confidence interval [CI] 0.32–0.89, p = 0.016) was an independent prognostic factor for diminished overall survival in patients with PDAC. By contrast, no statistical significance was found for FGF18 overexpression. In addition, the FGF8 protein level correlated with the factor resection margin (p = 0.042).

Conclusion

FGF8 is a promising target for new anticancer therapies using FGF inhibitors in pancreatic ductal adenocarcinomas.
Hinweise

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Main novel aspects
  • This is the first study of expression of FGF8 and FGF18 in pancreatic ductal adenocarcinoma
  • The patient cohort includes neoadjuvantly treated patients

Introduction

Pancreatic ductal adenocarcinoma (PDAC) is currently the 7th leading cause of cancer death, with more than 400,000 observed deaths annually worldwide [1, 2]. The incidence of PDAC is higher in more developed countries and in the elderly population [1, 3]. Despite the introduction of new therapeutic approaches combining multimodal treatment protocols and surgical resection, at only 8%, PDAC has the lowest 5‑year survival rate of all cancer types [47]. One of the most important causes of the devastating survival rate of PDAC lies in its late diagnosis. The majority of patients present with distant metastatic disease at the time of diagnosis and around one third of cases present with locally advanced disease [8]. Due to the increasing availability of diagnostic tools like computed tomography (CT), an increasing number of patients are diagnosed in an early locally advanced stage of disease and therefore qualify for neoadjuvant therapy, which has emerged as a standard treatment in borderline resectable PDAC [6, 9]. Although novel therapeutic combinations based on gemcitabine or FOLFIRINOX have shown promising results in all stages of disease, a large number of patients suffer from little to no efficacy based on the development of chemoresistance [10]. Patients with diabetes and chronic pancreatitis are more likely to suffer from PDAC. Furthermore, smoking, alcohol abuse, and a high fat and protein diet increase the risk of developing PDAC, underlining the crucial role of inflammation in pancreatic carcinogenesis which is characterized by desmoplasia-driven activation and differentiation of pancreatic stellate cells into pancreatic αSMA+/vimentin+ myofibroblasts [1113]. Beside the systemic inflammatory response (SIR), emerging evidence determined that inflammation-associated vital genes, signaling pathways, and growth factors such as PI3K (phosphatidylinositol), Ras-MAPK (mitogen-activated protein kinase), STAT (signal and activator of transcription), Wnt, EGF (epidermal growth factor), and FGF (fibroblast growth factor) are involved in the carcinogenesis and progression of PDAC [1421]. FGFs are peptide-like molecules which bind to their specific receptors (FGFR) on cell membranes to govern cell growth. FGFs can be found in numerous types of tissue and are known to promote fibroblast proliferation. Due to their high affinity for heparin, FGFs are also known as heparin-conjugate growth factors. The molecular structure of FGF proteins includes a heparin sulphate (HS) domain and a fibroblast growth factor receptor-binding domain. In mammals, 22 different FGFs are known today. Beside the biggest FGF subfamily, the canonical FGFs, one endocrine and one intracellular FGF subfamily exists and all FGFs mediate their cellular response via binding and activation of one of four FGFRs [14, 21]. A broad range of FGFs have been investigated in vitro and in vivo for their role and influence on PDAC, including the treatment response of pancreatic cancer cells to chemotherapy and the use of anti-FGF therapy, so called “ligand-traps” [14, 2229].
The prognostic role of the fibroblast growth factors (FGF) 8 and 18, both members of the FGF subfamily 8, were investigated in a number of malignancies [3035]. Whereas the majority of studies describe diminished patient prognosis in cancers overexpressing FGF8 and FGF18, a protective effect of FGF18 has been found for gastroesophageal adenocarcinomas [36]. Furthermore, there are increasing data on the use of FGF ligand traps and fibroblast growth factor receptor (FGFR) inhibitors to overcome chemoresistance in various cancers, including pancreatic tumors [3739]. However, no data on the expression of FGF8 and FGF18 in PADC are available to date. Therefore, the aim of this study was to investigate the expression rates and a possible prognostic role of FGF8 and FGF18 in a cohort of primarily resected and neoadjuvantly treated PDAC patients.

Materials and methods

Patients who underwent resection of PDAC between 1994 and 2012 at the Medical University of Vienna were identified from a prospectively maintained database. Patients with distant metastasis at the time of diagnosis or history of any other malignant disease were excluded. The study was approved by the ethics committee of the Medical University of Vienna, according to the declaration of Helsinki (EK 1518/2020). Patients with borderline resectable PDAC at the time of diagnosis received neoadjuvant treatment according to the recommendations of the interdisciplinary tumor board meetings at the Medical University of Vienna Tumor stage was determined according to the pathological tumor/node/metastasis (TNM) classification of the Union for International Cancer Control (UICC), 8th edition.
Immunohistochemistry (IHC) was performed as reported previously [36]. In brief, paraffin-embedded specimens fixed in 4% buffered formalin were used with 3‑µm thick histological sections. Expression of FGF8 and FGF18 was detected using polyclonal rabbit antibodies as follows: FGF8 antibody (Abcam®, Cambridge, UK, ab203030) in a dilution of 1:600 and FGF18 antibody (Assay Biotech®, Fremont, CA, USA, C12364) in a dilution of 1:500, respectively. Detection of the primary antibody was performed using a horseradish peroxidase (HRP)-labeled polymer system specific for mouse and rabbit IgG antibodies. The polymer complex was visualized using 3,3′-diaminobenzidine (DAB) and nuclei were counterstained using hematoxylin. All steps were performed according to the manufacturer’s protocols (Thermo Scientific™, Waltham, MA, USA; UltraVision LP Detection System HRP DAB). Stained sections were scanned using 3DHISTECH Ltd. (Budapest, Hungary) Pannoramic MIDI slides canner and analyzed and scored using Pannoramic Viewer 1.15.4 Software. Antibodies used in this study were optimized for PDAC on colorectal cancer and esophageal adenocarcinoma tissue with known expression from previously published studies [3638].
Statistical analysis was performed using the R statistical software, Vienna, Austria (version 3.6) with the survival package. To determine the cut-off value for CA19‑9, the optimal cutpoints package was used as appropriate [40, 41]. Overall survival (OS) was defined as the time between primary surgery and the patient’s death. Death from causes other than PDAC or survival until the end of observation were considered as censored observations. Uni- and multivariable analyses were conducted using the Cox proportional hazard model as appropriate. The Kaplan–Meier estimator analysis was performed using the survminer package for R statistical software [42]. The log-rank test was used to determine the significance of differences in survival times. Potential significance of correlations between clinicopathological factors and FGF8 and FGF18 expression levels were analyzed with the χ2 test. Non-parametric Kendall’s rank correlation was performed to investigate potential statistical dependence between FGF8 and FGF18.

Results

Tissue of 78 patients with pancreatic ductal adenocarcinoma was available for analysis. Mean age was 65 (22–85) years, 34 patients (43.6%) were females and 44 (56.4%) males. The most frequent tumor differentiation was (y)G2 in 53 (68.0%) patients. Most patients (53, 68.0%) showed (y)pT3 stage, 63 (80.8%) patients showed nodal involvement ((y)pN1), and 15 (19.2%) patients had received neoadjuvant chemotherapy. Of the 78 eligible cases, 40 (51.3%) and 45 (57.7%) cases showed high expression of FGF8 and FGF18, respectively (Fig. 1). Significant correlation was only observed between high expression of FGF8 and the factor resection margin (p = 0.042). Correlations between the expression of FGF8 and FGF18 and clinicopathological parameters are compiled in Table 1. Among all samples tested, high expression of FGF8 and FGF18 was found in 22 (28.2%) cases. Analysis of a potential correlation of high FGF8 and FGF18 expression found statistical significance (p = 0.036).
Table 1
Association of the expression of FGF8 and FGF18 with clinicopathologic parameters in pancreatic ductal adenocarcinoma
Factor
FGF8
  
FGF18
  
 
High
Low
p-value
High
Low
p-value
n = 78
40
38
 
45
33
 
Age, mean (years)
66.2
63.4
>0.1a
64.8
64.9
>0.1a
Sex
  
>0.1
  
>0.1
Male
21
23
17
27
Female
19
15
16
18
(y)pT
  
>0.1
  
>0.1
1
3
3
2
4
2
15
10
12
13
3
20
24
18
26
4
2
1
1
2
(y)pN
  
>0.1
  
>0.1
0
13
26
13
12
1
27
12
20
33
(y)G
  
>0.1
  
>0.1
1
3
3
4
2
2
26
22
20
28
3
11
13
9
15
R
  
0.042
  
>0.1
0
30
28
22
11
1
10
10
36
9
M
  
>0.1
  
>0.1
0
39
36
32
43
1
1
2
1
2
UICC staging
  
>0.1
  
>0.1
I
8
5
7
6
II
29
30
24
35
III
2
1
1
2
IV
1
2
1
2
Neoadjuvant treatment
  
>0.1
  
>0.1
No
31
7
25
39
Yes
7
33
8
6
Adjuvant treatment
  
>0.1
  
>0.1
No
24
29
21
32
Yes
16
9
12
13
Jaundice
  
>0.1
  
>0.1
No
12
14
13
13
Yes
28
24
20
32
CA 19‑9
  
>0.1
  
>0.1
≤156 kU/L
24
18
21
21
>156 kU/L
16
20
12
24
Nicotine
  
>0.1
  
>0.1
No
22
16
19
19
Yes
18
22
14
26
Pain
  
>0.1
  
>0.1
No
20
25
16
29
Yes
20
13
17
16
Pancreatitis
  
>0.1
  
>0.1
No
32
32
29
35
Yes
8
6
4
10
Diabetes
  
>0.1
  
>0.1
No
28
24
21
31
Yes
12
14
12
14
Stent
  
>0.1
  
>0.1
No
17
12
12
17
Yes
23
26
21
28
Surgical procedure
  
>0.1
  
>0.1
PPPD
21
22
20
23
Whipple
15
9
8
16
Distal resection
1
2
2
1
Total pancreatectomy
3
5
3
5
Localization
  
>0.1
  
>0.1
Head
34
30
28
36
Corpus
2
4
2
4
Cauda
4
4
3
5
UICC Union for International Cancer Control, PPPD pylorus preserving partial duodenopancreatectomy, FGF fibroblast growth factor, CA carbohydrate antigen, R resection status
aUsing t-test
Median survival time was 30 months (range 0–153 months) and disease recurrence occurred in 70 (88.9%) patients. Survival analysis using Kaplan–Meier curves for visualization found significantly shorter OS rates for patients with high FGF8 expression (p = 0.04; Fig. 2). No significance could be found for high FGF18 expression and OS (Fig. 2). Three- and 5‑year OS were 15 (16.7%) months and 2 (2.2%) months, respectively. Univariable Cox proportion hazard regression analysis revealed that FGF8 (HR 0.62, 95% CI 0.38–0.99, p = 0.04), pain (HR 1.79, 95% CI 1.15–2.76, p = 0.009), and surgical procedure (HR 4.41, 95% CI 1.32–14.70, p = 0.02) were significantly associated with OS (Table 2). In multivariable analysis including patients’ age and gender, UICC staging, tumor differentiation, resection margin, and neoadjuvant and adjuvant treatment, FGF8 (HR 0.53, 95% CI 0.32–0.89, p = 0.016) expression remained the only independent prognostic factor for OS (Table 3). In a separate multivariable Cox regression model for FGF18, using the same cofactors as for FGF8, no statistical significance was observed for any of the included factors (Table 4).
Table 2
Univariate Cox regression analysis estimating the influence of the expression of FGF8 and FGF18 and clinicopathological parameters on overall survival and disease-free survival in patients with ductal adenocarcinoma of the pancreas
 
Overall survival
RR
CI (95%)
p-value
FGF8
High vs. low
0.62
0.38–0.99
0.04
FGF18
High vs. low
0.88
0.56–1.40
>0.1
Age
0.99
0.98–1.02
>0.1
Sex
Male vs. female
0.88
0.58–1.35
>0.1
T staging
1 vs. 3
0.51
0.14–1.86
>0.1
2 vs. 3
0.59
0.20–1.72
>0.1
4 vs. 3
0.57
0.20–1.59
>0.1
N staging
1 vs. 0
1.01
0.64–1.60
>0.1
Grading
1 vs. 2
1.57
0.74–3.35
>0.1
3 vs. 2
1.26
0.80–2.00
>0.1
R
1 vs. 0
1.11
0.90–1.80
>0.1
M staging
1 vs. 0
0.28
0.07–1.17
0.08
UICC stage
I vs. II
1.41
0.80–2.47
>0.1
III vs. II
1.79
0.64–4.96
>0.1
IV vs. II
0.3
0.07–1.24
0.09
Yes vs. no
1.61
0.92–2.82
0.09
Adjuvant treatment
Yes vs. no
1.02
0.66–1.59
>0.1
Jaundice
Yes vs. no
0.97
0.63–1.50
>0.1
CA 19‑9
≥114 vs. <114 kU/L
0.86
0.56–1.32
>0.1
Nicotine
Yes vs. no
1.25
0.82–1.89
>0.1
Pain
Yes vs. no
1.79
1.15–2.76
0.01
Pancreatitis
Yes vs. no
1.21
0.70–2.10
>0.1
Diabetes
Yes vs. no
1.16
0.74–1.83
>0.1
Stent
Yes vs. no
1.16
0.75–1.79
>0.1
Surgical procedure PPPD (reference)
Whipple
1.52
0.66–2.47
0.09
Distal resection
4.41
1.32–1.95
0.02
Total pancreatectomy
1.03
0.54–1.95
>0.1
Localization
Corpus vs. head
1.51
0.68–3.33
>0.1
Cauda vs. head
0.91
0.48–1.71
>0.1
UICC Union for International Cancer Control, CI confidence interval, RR relative risk, PPPD pylorus-preserving pancreaticoduodenectomy, FGF fibroblast growth factor, CA carbohydrate antigen, R resection status
Table 3
Multivariate Cox regression analysis estimating the influence of FGF8 expression and clinicopathological parameters on overall survival in patients with ductal adenocarcinoma of the pancreas
Overall survival
 
RR
CI (95%)
p-value
FGF8
High vs. low
0.53
0.32–0.89
0.02
Age
0.99
0.97–1.02
>0.1
Sex
Male vs. female
0.87
0.53–1.45
>0.1
UICC stage
I + II vs. III + IV
1.47
0.85–2.56
>0.1
Grading
1 vs. 2
1.66
0.65–4.23
>0.1
3 vs. 2
1.45
0.86–2.42
>0.1
R
1 vs. 0
1.06
0.61–1.83
>0.1
Yes vs. no
1.76
0.93–3.36
>0.1
Adjuvant treatment
Yes vs. no
0.87
0.51–1.51
>0.1
UICC Union for International Cancer Control, CI confidence interval, RR relative risk, FGF fibroblast growth factor, R resection status
Table 4
Multivariate Cox regression analysis estimating the influence of FGF18 expression and clinicopathological parameters on overall survival in patients with ductal adenocarcinoma of the pancreas
Overall survival
 
RR
CI (95%)
p-value
FGF18
High vs. low
0.75
0.44–1.25
>0.1
Age
0.99
0.98–1.02
>0.1
Sex
Male vs. female
0.99
0.60–1.63
>0.1
UICC stage
I + II vs. III + IV
1.52
0.86–2.69
>0.1
Grading
1 vs. 2
1.80
0.71–4.56
>0.1
3 vs. 2
1.28
0.76–2.17
>0.1
R
1 vs. 0
1.17
0.66–2.07
>0.1
Yes vs. no
1.82
0.94–3.53
0.08
Adjuvant treatment
Yes vs. no
1.09
0.64–1.87
>0.1
UICC Union for International Cancer Control, CI confidence interval, RR relative risk, FGF fibroblast growth factor, R resection status

Discussion

Pancreatic ductal adenocarcinoma is one of the leading causes of cancer-related deaths worldwide. The majority of patients suffering from PDAC are diagnosed with advanced or metastatic disease and only 15 to 20% of patients are suitable to receive primary resection [5]. Even though the combination of surgery and multimodal therapies has resulted in improvements in the treatment of patients with PDAC over recent decades, survival rates remain poor. Therefore, better understanding of the pathogenesis of PDAC is urgently needed to develop new diagnostic and improved treatment approaches.
The family of FGFs consists of seven subfamilies, categorized by their way of secretion, sequence similarities, and functional properties [43]. Physiologically, FGFs are involved in cell proliferation and angiogenesis. The canonical FGF8 subfamily consists of FGF8, FGF17, and FGF18, which bind and activate FGFRs with heparin/heparin sulfate as a cofactor [44]. The FGF8 gene is encoded on chromosome 10q24.32 and participates in embryonic development, mediating the epithelial to mesenchymal and mesenchymal to epithelial transitions. Furthermore, FGF8 is involved in craniopharyngeal and cardiovascular development. The FGF18 gene is encoded on chromosome 5q35.1 and like FGF8 it is involved in embryonic development and morphogenesis of blood vessels. Furthermore, it acts as a pleiotropic growth factor for upper gastrointestinal organs. Alterations of FGF signaling might be followed by FGFR gene amplification and fusion, mutation, or by FGF and/or FGFR overexpression. Due to these characteristics, overexpression of FGFs can promote carcinogenesis and distant metastasis, and therefore have a fundamental role in cancer [21]. In a number of malignancies, including gastric cancer, gastroesophageal adenocarcinoma, and PDAC, the prognostic role of aberrant FGF expression was investigated [30, 35, 36, 38, 39]. However, to date, only few data on the expression of FGF8 and FGF18 in PDAC are available [23]. Even though promising data on the preclinical use of anti-FGF therapies (ligand traps) exist, hardly any data exist on the blockage of FGF8 and FGF18 [13, 45, 46].
Due to the introduction and routine use of chemotherapeutic drugs, such as gemcitabine, nab-paclitaxel, oxaliplatin, irinotecan, leucovorin, and fluorouracil, in both the neoadjuvant and adjuvant settings, improved patient survival rates could be seen over the past few decades. Over the past decade, gemcitabine-treated and modified FOLFIRINOX (oxaliplatin, irinotecan, leucovorin, and fluorouracil)-treated patients showed satisfying improvements in survival rates. Therefore, these two chemotherapy regimens were established as standard for patients with PDAC [47]. However, patients still suffer from severe side effects and frustrating outcomes related to poor therapeutic results, often based on the development of chemical resistance. Particularly the development of resistance to chemotherapy has emerged as one of the biggest challenges in PDAC therapy. Causing disease recurrence in the majority of patients with PDAC, the investigation of the molecular mechanisms by which PDAC cells develop resistance to chemotherapeutic agents became the aim of a number of studies. Multiple mechanisms and factors play an important role in the development of chemical resistance; however, the development of new and durable treatment options still lags behind [10]. So far, research on molecularly targeted therapies for PDAC have focused on EGFR, VEGF, and RAS pathways, using agents such as erlotinib, cetuximab, and panitumumab. However, no clear benefit in terms of patients’ overall or disease-free survival could be achieved to date [20, 48, 49].
To the best of our knowledge, this is the first study investigating the prognostic role of FGF8 and FGF18 in PDAC using IHC on tumor tissue. Based on our findings that high expression of FGF8 is independently associated with diminished overall survival, one can hypothesize that FGF8 represents a promising target for further investigations in anti-PDAC therapy, especially to overcome the nascent problem of chemoresistance.

Acknowledgements

The authors would like to thank Prof. Brigitte Marian for supporting this study with her enormous knowledge on fibroblast growth factors and their receptors.

Conflict of interest

G. Jomrich, L. Wilfing, S. Radosavljevic, A. Parak, D. Winkler, G. Timelthaler, M. Schindl, S.F. Schoppmann, and B. Klösch declare that they have no competing interests.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://​creativecommons.​org/​licenses/​by/​4.​0/​.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Literatur
1.
Zurück zum Zitat Are C, Chowdhury S, Ahmad H, Ravipati A, Song T, Shrikandhe S, et al. Predictive global trends in the incidence and mortality of pancreatic cancer based on geographic location, socio-economic status, and demographic shift. J Surg Oncol. 2016;114(6):736–42. PubMed Are C, Chowdhury S, Ahmad H, Ravipati A, Song T, Shrikandhe S, et al. Predictive global trends in the incidence and mortality of pancreatic cancer based on geographic location, socio-economic status, and demographic shift. J Surg Oncol. 2016;114(6):736–42. PubMed
2.
Zurück zum Zitat Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. CrossRef Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. CrossRef
3.
Zurück zum Zitat Ryan DP, Hong TS, Bardeesy N. Pancreatic adenocarcinoma. N Engl J Med. 2014;371(22):2140–1. PubMed Ryan DP, Hong TS, Bardeesy N. Pancreatic adenocarcinoma. N Engl J Med. 2014;371(22):2140–1. PubMed
4.
Zurück zum Zitat Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30. PubMed Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30. PubMed
5.
Zurück zum Zitat Djanani A, Schmiderer A, Niederreiter L, Niederreiter M, Tilg H. Management of ductal pancreatic cancer: the oncologists view: systemic treatment options in 2018. Eur Surg. 2019;51(3):135–8. Djanani A, Schmiderer A, Niederreiter L, Niederreiter M, Tilg H. Management of ductal pancreatic cancer: the oncologists view: systemic treatment options in 2018. Eur Surg. 2019;51(3):135–8.
6.
Zurück zum Zitat Klaiber U, Roth S, Hackert T, Neoptolemos JP. Evolution of oncosurgical management of pancreatic cancer. Eur Surg. 2019;51(3):165–73. Klaiber U, Roth S, Hackert T, Neoptolemos JP. Evolution of oncosurgical management of pancreatic cancer. Eur Surg. 2019;51(3):165–73.
7.
Zurück zum Zitat Sahakyan MA, Labori KJ, Primavesi F, Soreide K, Stattner S, Edwin B. Minimally invasive pancreatic surgerywhere are we going? Eur Surg. 2019;51(3):98–104. Sahakyan MA, Labori KJ, Primavesi F, Soreide K, Stattner S, Edwin B. Minimally invasive pancreatic surgerywhere are we going? Eur Surg. 2019;51(3):98–104.
8.
Zurück zum Zitat Huang L, Jansen L, Balavarca Y, Molina-Montes E, Babaei M, van der Geest L, et al. Resection of pancreatic cancer in Europe and USA: an international large-scale study highlighting large variations. Gut. 2019;68(1):130–9. PubMed Huang L, Jansen L, Balavarca Y, Molina-Montes E, Babaei M, van der Geest L, et al. Resection of pancreatic cancer in Europe and USA: an international large-scale study highlighting large variations. Gut. 2019;68(1):130–9. PubMed
9.
Zurück zum Zitat Gassner EM, Poskaite P. Imaging response evaluation after novel neoadjuvant treatments of pancreatic cancer. Eur Surg. 2019;51(3):146–52. Gassner EM, Poskaite P. Imaging response evaluation after novel neoadjuvant treatments of pancreatic cancer. Eur Surg. 2019;51(3):146–52.
10.
Zurück zum Zitat Zeng S, Pottler M, Lan B, Grutzmann R, Pilarsky C, Yang H. Chemoresistance in pancreatic cancer. Int J Mol Sci. 2019;20(18):4504. PubMedCentral Zeng S, Pottler M, Lan B, Grutzmann R, Pilarsky C, Yang H. Chemoresistance in pancreatic cancer. Int J Mol Sci. 2019;20(18):4504. PubMedCentral
11.
Zurück zum Zitat Kirkegard J, Mortensen FV, Cronin-Fenton D. Chronic pancreatitis and pancreatic cancer risk: a systematic review and meta-analysis. Am J Gastroenterol. 2017;112(9):1366–72. PubMed Kirkegard J, Mortensen FV, Cronin-Fenton D. Chronic pancreatitis and pancreatic cancer risk: a systematic review and meta-analysis. Am J Gastroenterol. 2017;112(9):1366–72. PubMed
12.
Zurück zum Zitat Zhang JJ, Jia JP, Shao Q, Wang YK. Diabetes mellitus and risk of pancreatic cancer in China: a meta-analysis based on 26 case-control studies. Prim Care Diabetes. 2019;13(3):276–82. PubMed Zhang JJ, Jia JP, Shao Q, Wang YK. Diabetes mellitus and risk of pancreatic cancer in China: a meta-analysis based on 26 case-control studies. Prim Care Diabetes. 2019;13(3):276–82. PubMed
13.
Zurück zum Zitat Presta M, Chiodelli P, Giacomini A, Rusnati M, Ronca R. Fibroblast growth factors (FGFs) in cancer: FGF traps as a new therapeutic approach. Pharmacol Ther. 2017;179:171–87. PubMed Presta M, Chiodelli P, Giacomini A, Rusnati M, Ronca R. Fibroblast growth factors (FGFs) in cancer: FGF traps as a new therapeutic approach. Pharmacol Ther. 2017;179:171–87. PubMed
14.
Zurück zum Zitat Kang X, Lin Z, Xu M, Pan J, Wang ZW. Deciphering role of FGFR signalling pathway in pancreatic cancer. Cell Prolif. 2019;52(3):e12605. PubMedPubMedCentral Kang X, Lin Z, Xu M, Pan J, Wang ZW. Deciphering role of FGFR signalling pathway in pancreatic cancer. Cell Prolif. 2019;52(3):e12605. PubMedPubMedCentral
15.
Zurück zum Zitat Gruber ES, Jomrich G, Kaider A, Gnant M, Sahora K, Schindl M. The prognostic index independently predicts survival in patients with pancreatic ductal adenocarcinoma undergoing resection. Ann Surg Oncol. 2020;27(6):2017–24. PubMedPubMedCentral Gruber ES, Jomrich G, Kaider A, Gnant M, Sahora K, Schindl M. The prognostic index independently predicts survival in patients with pancreatic ductal adenocarcinoma undergoing resection. Ann Surg Oncol. 2020;27(6):2017–24. PubMedPubMedCentral
16.
Zurück zum Zitat Jomrich G, Gruber ES, Winkler D, Hollenstein M, Gnant M, Sahora K, et al. Systemic immune-inflammation index (SII) predicts poor survival in pancreatic cancer patients undergoing resection. J Gastrointest Surg. 2020;24(3):610–8. PubMed Jomrich G, Gruber ES, Winkler D, Hollenstein M, Gnant M, Sahora K, et al. Systemic immune-inflammation index (SII) predicts poor survival in pancreatic cancer patients undergoing resection. J Gastrointest Surg. 2020;24(3):610–8. PubMed
17.
Zurück zum Zitat Ebrahimi S, Hosseini M, Shahidsales S, Maftouh M, Ferns GA, Ghayour-Mobarhan M, et al. Targeting the Akt/PI3K signaling pathway as a potential therapeutic strategy for the treatment of pancreatic cancer. Curr Med Chem. 2017;24(13):1321–31. PubMed Ebrahimi S, Hosseini M, Shahidsales S, Maftouh M, Ferns GA, Ghayour-Mobarhan M, et al. Targeting the Akt/PI3K signaling pathway as a potential therapeutic strategy for the treatment of pancreatic cancer. Curr Med Chem. 2017;24(13):1321–31. PubMed
18.
Zurück zum Zitat Hao C, Li Z, Zhang X, Zhang H, Shang H, Bao J, et al. Expression and clinical significance of EGF and TGF-alpha in chronic pancreatitis and pancreatic cancer. Minerva Endocrinol. 2018;43(3):253–8. PubMed Hao C, Li Z, Zhang X, Zhang H, Shang H, Bao J, et al. Expression and clinical significance of EGF and TGF-alpha in chronic pancreatitis and pancreatic cancer. Minerva Endocrinol. 2018;43(3):253–8. PubMed
20.
Zurück zum Zitat Soreide K, Primavesi F, Labori KJ, Watson MM, Stattner S. Molecular biology in pancreatic ductal adenocarcinoma: implications for future diagnostics and therapy. Eur Surg. 2019;51(3):126–34. Soreide K, Primavesi F, Labori KJ, Watson MM, Stattner S. Molecular biology in pancreatic ductal adenocarcinoma: implications for future diagnostics and therapy. Eur Surg. 2019;51(3):126–34.
21.
Zurück zum Zitat Turner N, Grose R. Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer. 2010;10(2):116–29. PubMed Turner N, Grose R. Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer. 2010;10(2):116–29. PubMed
22.
Zurück zum Zitat Abramovitz L, Rubinek T, Ligumsky H, Bose S, Barshack I, Avivi C, et al. KL1 internal repeat mediates klotho tumor suppressor activities and inhibits bFGF and IGF‑I signaling in pancreatic cancer. Clin Cancer Res. 2011;17(13):4254–66. PubMed Abramovitz L, Rubinek T, Ligumsky H, Bose S, Barshack I, Avivi C, et al. KL1 internal repeat mediates klotho tumor suppressor activities and inhibits bFGF and IGF‑I signaling in pancreatic cancer. Clin Cancer Res. 2011;17(13):4254–66. PubMed
23.
Zurück zum Zitat Kornmann M, Beger HG, Korc M. Role of fibroblast growth factors and their receptors in pancreatic cancer and chronic pancreatitis. Pancreas. 1998;17(2):169–75. PubMed Kornmann M, Beger HG, Korc M. Role of fibroblast growth factors and their receptors in pancreatic cancer and chronic pancreatitis. Pancreas. 1998;17(2):169–75. PubMed
24.
Zurück zum Zitat Leung HY, Gullick WJ, Lemoine NR. Expression and functional activity of fibroblast growth factors and their receptors in human pancreatic cancer. Int J Cancer. 1994;59(5):667–75. PubMed Leung HY, Gullick WJ, Lemoine NR. Expression and functional activity of fibroblast growth factors and their receptors in human pancreatic cancer. Int J Cancer. 1994;59(5):667–75. PubMed
25.
Zurück zum Zitat Liu B, Wang Z, Li HY, Zhang B, Ping B, Li YY. Pim‑3 promotes human pancreatic cancer growth by regulating tumor vasculogenesis. Oncol Rep. 2014;31(6):2625–34. PubMed Liu B, Wang Z, Li HY, Zhang B, Ping B, Li YY. Pim‑3 promotes human pancreatic cancer growth by regulating tumor vasculogenesis. Oncol Rep. 2014;31(6):2625–34. PubMed
26.
Zurück zum Zitat Niu J, Chang Z, Peng B, Xia Q, Lu W, Huang P, et al. Keratinocyte growth factor/fibroblast growth factor-7-regulated cell migration and invasion through activation of NF-kappaB transcription factors. J Biol Chem. 2007;282(9):6001–11. PubMed Niu J, Chang Z, Peng B, Xia Q, Lu W, Huang P, et al. Keratinocyte growth factor/fibroblast growth factor-7-regulated cell migration and invasion through activation of NF-kappaB transcription factors. J Biol Chem. 2007;282(9):6001–11. PubMed
27.
Zurück zum Zitat Torres C, Perales S, Alejandre MJ, Iglesias J, Palomino RJ, Martin M, et al. Serum cytokine profile in patients with pancreatic cancer. Pancreas. 2014;43(7):1042–9. PubMed Torres C, Perales S, Alejandre MJ, Iglesias J, Palomino RJ, Martin M, et al. Serum cytokine profile in patients with pancreatic cancer. Pancreas. 2014;43(7):1042–9. PubMed
28.
Zurück zum Zitat Vickers SM, MacMillan-Crow LA, Green M, Ellis C, Thompson JA. Association of increased immunostaining for inducible nitric oxide synthase and nitrotyrosine with fibroblast growth factor transformation in pancreatic cancer. Arch Surg. 1999;134(3):245–51. PubMed Vickers SM, MacMillan-Crow LA, Green M, Ellis C, Thompson JA. Association of increased immunostaining for inducible nitric oxide synthase and nitrotyrosine with fibroblast growth factor transformation in pancreatic cancer. Arch Surg. 1999;134(3):245–51. PubMed
29.
Zurück zum Zitat Yamanaka Y, Friess H, Buchler M, Beger HG, Uchida E, Onda M, et al. Overexpression of acidic and basic fibroblast growth factors in human pancreatic cancer correlates with advanced tumor stage. Cancer Res. 1993;53(21):5289–96. PubMed Yamanaka Y, Friess H, Buchler M, Beger HG, Uchida E, Onda M, et al. Overexpression of acidic and basic fibroblast growth factors in human pancreatic cancer correlates with advanced tumor stage. Cancer Res. 1993;53(21):5289–96. PubMed
30.
Zurück zum Zitat Dorkin TJ, Robinson MC, Marsh C, Bjartell A, Neal DE, Leung HY. FGF8 over-expression in prostate cancer is associated with decreased patient survival and persists in androgen independent disease. Oncogene. 1999;18(17):2755–61. PubMed Dorkin TJ, Robinson MC, Marsh C, Bjartell A, Neal DE, Leung HY. FGF8 over-expression in prostate cancer is associated with decreased patient survival and persists in androgen independent disease. Oncogene. 1999;18(17):2755–61. PubMed
31.
Zurück zum Zitat Gauglhofer C, Sagmeister S, Schrottmaier W, Fischer C, Rodgarkia-Dara C, Mohr T, et al. Up-regulation of the fibroblast growth factor 8 subfamily in human hepatocellular carcinoma for cell survival and neoangiogenesis. Hepatology. 2011;53(3):854–64. PubMed Gauglhofer C, Sagmeister S, Schrottmaier W, Fischer C, Rodgarkia-Dara C, Mohr T, et al. Up-regulation of the fibroblast growth factor 8 subfamily in human hepatocellular carcinoma for cell survival and neoangiogenesis. Hepatology. 2011;53(3):854–64. PubMed
32.
Zurück zum Zitat Tanaka A, Kamiakito T, Takayashiki N, Sakurai S, Saito K. Fibroblast growth factor 8 expression in breast carcinoma: associations with androgen receptor and prostate-specific antigen expressions. Virchows Arch. 2002;441(4):380–4. PubMed Tanaka A, Kamiakito T, Takayashiki N, Sakurai S, Saito K. Fibroblast growth factor 8 expression in breast carcinoma: associations with androgen receptor and prostate-specific antigen expressions. Virchows Arch. 2002;441(4):380–4. PubMed
33.
Zurück zum Zitat Sonvilla G, Allerstorfer S, Stattner S, Karner J, Klimpfinger M, Fischer H, et al. FGF18 in colorectal tumour cells: autocrine and paracrine effects. Carcinogenesis. 2008;29(1):15–24. PubMed Sonvilla G, Allerstorfer S, Stattner S, Karner J, Klimpfinger M, Fischer H, et al. FGF18 in colorectal tumour cells: autocrine and paracrine effects. Carcinogenesis. 2008;29(1):15–24. PubMed
34.
Zurück zum Zitat Wei W, Mok SC, Oliva E, Kim SH, Mohapatra G, Birrer MJ. FGF18 as a prognostic and therapeutic biomarker in ovarian cancer. J Clin Invest. 2013;123(10):4435–48. PubMedPubMedCentral Wei W, Mok SC, Oliva E, Kim SH, Mohapatra G, Birrer MJ. FGF18 as a prognostic and therapeutic biomarker in ovarian cancer. J Clin Invest. 2013;123(10):4435–48. PubMedPubMedCentral
35.
Zurück zum Zitat Zhang J, Zhou Y, Huang T, Wu F, Pan Y, Dong Y, et al. FGF18, a prominent player in FGF signaling, promotes gastric tumorigenesis through autocrine manner and is negatively regulated by miR-590-5p. Oncogene. 2019;38(1):33–46. PubMed Zhang J, Zhou Y, Huang T, Wu F, Pan Y, Dong Y, et al. FGF18, a prominent player in FGF signaling, promotes gastric tumorigenesis through autocrine manner and is negatively regulated by miR-590-5p. Oncogene. 2019;38(1):33–46. PubMed
38.
Zurück zum Zitat Harpain F, Ahmed MA, Hudec X, Timelthaler G, Jomrich G, Mullauer L, et al. FGF8 induces therapy resistance in neoadjuvantly radiated rectal cancer. J Cancer Res Clin Oncol. 2019;145(1):77–86. PubMed Harpain F, Ahmed MA, Hudec X, Timelthaler G, Jomrich G, Mullauer L, et al. FGF8 induces therapy resistance in neoadjuvantly radiated rectal cancer. J Cancer Res Clin Oncol. 2019;145(1):77–86. PubMed
39.
Zurück zum Zitat Zhou Y, Wu C, Lu G, Hu Z, Chen Q, Du X. FGF/FGFR signaling pathway involved resistance in various cancer types. J Cancer. 2020;11(8):2000–7. PubMedPubMedCentral Zhou Y, Wu C, Lu G, Hu Z, Chen Q, Du X. FGF/FGFR signaling pathway involved resistance in various cancer types. J Cancer. 2020;11(8):2000–7. PubMedPubMedCentral
40.
Zurück zum Zitat R Development Core Team. A language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2018. R Development Core Team. A language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2018.
41.
Zurück zum Zitat Therneau T. A package for survival analysis. 2015. p. 2.38. Therneau T. A package for survival analysis. 2015. p. 2.38.
42.
Zurück zum Zitat Kassambara AKM, Biecek P, Fabian S. survminer: Drawing Survival Curves using “ggplot2”. 2019. Kassambara AKM, Biecek P, Fabian S. survminer: Drawing Survival Curves using “ggplot2”. 2019.
43.
Zurück zum Zitat Zhang X, Ibrahimi OA, Olsen SK, Umemori H, Mohammadi M, Ornitz DM. Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family. J Biol Chem. 2006;281(23):15694–700. PubMedPubMedCentral Zhang X, Ibrahimi OA, Olsen SK, Umemori H, Mohammadi M, Ornitz DM. Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family. J Biol Chem. 2006;281(23):15694–700. PubMedPubMedCentral
44.
Zurück zum Zitat Ornitz DM, Itoh N. The fibroblast growth factor signaling pathway. Wiley Interdiscip Rev Dev Biol. 2015;4(3):215–66. PubMedPubMedCentral Ornitz DM, Itoh N. The fibroblast growth factor signaling pathway. Wiley Interdiscip Rev Dev Biol. 2015;4(3):215–66. PubMedPubMedCentral
45.
Zurück zum Zitat Tanaka A, Furuya A, Yamasaki M, Hanai N, Kuriki K, Kamiakito T, et al. High frequency of fibroblast growth factor (FGF) 8 expression in clinical prostate cancers and breast tissues, immunohistochemically demonstrated by a newly established neutralizing monoclonal antibody against FGF 8. Cancer Res. 1998;58(10):2053–6. PubMed Tanaka A, Furuya A, Yamasaki M, Hanai N, Kuriki K, Kamiakito T, et al. High frequency of fibroblast growth factor (FGF) 8 expression in clinical prostate cancers and breast tissues, immunohistochemically demonstrated by a newly established neutralizing monoclonal antibody against FGF 8. Cancer Res. 1998;58(10):2053–6. PubMed
46.
Zurück zum Zitat Wang L, Park H, Chhim S, Ding Y, Jiang W, Queen C, et al. A novel monoclonal antibody to fibroblast growth factor 2 effectively inhibits growth of hepatocellular carcinoma xenografts. Mol Cancer Ther. 2012;11(4):864–72. PubMedPubMedCentral Wang L, Park H, Chhim S, Ding Y, Jiang W, Queen C, et al. A novel monoclonal antibody to fibroblast growth factor 2 effectively inhibits growth of hepatocellular carcinoma xenografts. Mol Cancer Ther. 2012;11(4):864–72. PubMedPubMedCentral
47.
Zurück zum Zitat de Sousa Cavalcante L, Monteiro G. Gemcitabine: metabolism and molecular mechanisms of action, sensitivity and chemoresistance in pancreatic cancer. Eur J Pharmacol. 2014;741:8–16. PubMed de Sousa Cavalcante L, Monteiro G. Gemcitabine: metabolism and molecular mechanisms of action, sensitivity and chemoresistance in pancreatic cancer. Eur J Pharmacol. 2014;741:8–16. PubMed
48.
Zurück zum Zitat Sheahan AV, Biankin AV, Parish CR, Khachigian LM. Targeted therapies in the management of locally advanced and metastatic pancreatic cancer: a systematic review. Oncotarget. 2018;9(30):21613–27. PubMedPubMedCentral Sheahan AV, Biankin AV, Parish CR, Khachigian LM. Targeted therapies in the management of locally advanced and metastatic pancreatic cancer: a systematic review. Oncotarget. 2018;9(30):21613–27. PubMedPubMedCentral
49.
Zurück zum Zitat Liu H, Zhang B, Sun Z. Spectrum of EGFR aberrations and potential clinical implications: insights from integrative pan-cancer analysis. Cancer Commun. 2020;40(1):43–59. Liu H, Zhang B, Sun Z. Spectrum of EGFR aberrations and potential clinical implications: insights from integrative pan-cancer analysis. Cancer Commun. 2020;40(1):43–59.
Metadaten
Titel
Fibroblast growth factor 8 overexpression is predictive of poor prognosis in pancreatic ductal adenocarcinoma
verfasst von
Gerd Jomrich
Lavinia Wilfing
Sanja Radosavljevic
Ario Parak
Daniel Winkler
Gerald Timelthaler
Martin Schindl
Sebastian F. Schoppmann
Bernhard Klösch
Publikationsdatum
08.10.2020
Verlag
Springer Vienna
Erschienen in
European Surgery / Ausgabe 6/2020
Print ISSN: 1682-8631
Elektronische ISSN: 1682-4016
DOI
https://doi.org/10.1007/s10353-020-00669-6